NEWS ROOM

April 13, 2018

GlaxoSmithKline (GSK) said today it will hand off its rare disease gene therapy portfolio — including its European-approved gene therapy Strimvelis™ —...

Please reload

ARCHIVE
Please reload

SEARCH BY TAGS
Please reload

FOLLOW US
4BIO CAPITAL is a trade name of 4BIO Ventures Management Ltd, which is authorised and regulated by the Financial Conduct Authority, register number 775193
© 2015-2020 by 4BIO Ventures Management Ltd